1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Spain >
  5. AgomAb Therapeutics Acquires Origo Biopharma

M&A Deal Summary

AgomAb Therapeutics Acquires Origo Biopharma

On October 28, 2021, AgomAb Therapeutics acquired life science company Origo Biopharma

Acquisition Highlights
  • This is AgomAb Therapeutics’ 1st transaction in the Life Science sector.
  • This is AgomAb Therapeutics’ 1st transaction in Spain.

M&A Deal Summary
Date 2021-10-28
Target Origo Biopharma
Sector Life Science
Buyer(s) AgomAb Therapeutics
Deal Type Add-on Acquisition

Target

Origo Biopharma

Fonte Diaz, Spain
Origo Biopharma is a clinical stage biotechnology company developing organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway for the treatment of fibrosis-related disorders. Origo Biopharma is based in Fonte Diaz, Spain.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

AgomAb Therapeutics

Ghent, Belgium
Category Company
Founded 2017
Sector Life Science
DESCRIPTION

AgomAb Therapeutics is a biotherapeutics company developing agonistic antibodies for the regeneration of damaged tissues. AgomAb Therapeutics was founded in 2017 and is based in Ghent, Belgium.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: Spain M&A 1 of 1
Year: 2021 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal